Dyax Corp. (DYAX)

12/01/2009 FDA Class 2

Several exciting things in the pipeline, could easily double. I also like SNGX for a speculative biotech pick.

until drug approval

Huge potential here! FDA set a new date for DYAX's lead cantidate to December. I value the stock price at just above $10. This pitch is made a price of $1.99 per share.

becon 800

JUNK

With DYAX currently trading at low levels ($1.85/share, 52 week low is $1.80), i have made a small cash position in the company. This biotech company is led by an excellent management team and it seems with a final thumbs up from the FDA on DX-88 the company should thrive going forward into the long-term. SHould be a great 3-5 year investment, with wonderful potential to outperform S&P.

TheBank

Looking toward mid-late March and the FDA announcement on DX-88...trials look good, but the FDA has been cracking down lately so we'll see what they say...Has a good model of renting out patents and technology while also working development.

Dyax is a prickly pear of a baby biotech. Its succulent interior is irresistible, yet no matter how carefully it is approached one always seems to wind up with little spines in one's fingertips. I've been fortunate not to take any permanent injury in my prior plays on Dyax, with some help from the falling S&P. The share price this week has been extremely irrational, even for a small cap biotech. The negative FDA commentary on the phase III trials of DX-88 should have crushed the stock on Monday, but instead it rebounded to its three month high. And then today a 12% drop for no clear reason, providing an excellent entry point in anticipation of the FDA review panel meeting tomorrow. I'm following the Ligand model here, where the advisory panel completely disregarded negative FDA position papers and came out with a 16-0 vote in favor of approval. Of course, that may not translate into subsequent approval but should provide a lift back over 4 in the short-term. I'm going to have to play every peak and trough of this stock right to have a chance of catching Shoreham, who's had them by the nads over the last year or so.

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

great bio-tech partners - with lots of "magic beans" in pipeline

better off investing in magic beans

finding a partner to sell their top drug will boost the stock (the successful completion of phase III sent the stock up by 50% in a day, but that didn't last. Make use of it)

Well organized and focused

Hot New Products....stock took a beating....when Genzyme deal feel through...This stock due for a nice come back....sell on announcement

Too many promising projects inside their pipeline.

Development of new medicine, pending outcome of further research and medical experimentation.

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Now it is looking like the money they've spent is resulting in justification...it comes at a good time.

If it gets approved money will flow.